Article Details

AstraZeneca's dapagliflozin can “significantly” reduce risk of cardiovascular death in patients ...

Retrieved on: 2022-05-23 11:32:50

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's dapagliflozin can “significantly” reduce risk of cardiovascular death in patients .... View article details on HISWAI: https://www.financialexpress.com/healthcare/news-healthcare/astrazenecas-dapagliflozin-can-significantly-reduce-risk-of-cardiovascular-death-in-patients-deliver-phase-iii-trial-results-show/2534916/

Excerpt

The high-level results from the DELIVER Phase III trial released on Monday show that AstraZeneca's dapagliflozin has reached a statistically ...

Article found on: www.financialexpress.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up